Viveve markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. The company is transitioning from NASDAQ to OTC markets, reflecting significant operational challenges and a severe deterioration in market valuation from historical levels.
Cyborg Score Rationale
The stock price as of December 31, 2025 was $0.0001 with a market capitalization of only $1,072. The company faces severe financial distress with virtually no equity value and operates on OTC markets.
Top Insights
52-week range from $0.0001 to $0.02 indicates extreme volatility
Company was founded in 2005 and is headquartered in Englewood, Colorado
The company has 47 employees
Viveve is scheduled to release earnings on March 20, 2026
Named Competitors
Radiofrequency Medical Devices — Established players in non-invasive medical treatments
Women's Health Solutions — Companies with broader gynecological treatment portfolios
Recent Developments
(Mar 2026) Earnings report scheduled for March 20, 2026
(Dec 2025) Stock trading at penny stock levels ($0.0001-$0.0002)
(2022) PURSUIT pivotal trial for female stress urinary incontinence completed
Open the full interactive Viveve Medical, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.